Condition Directory

Lymphoma clinical trials

Directory of U.S. ClinicalTrials.gov public records for Lymphoma. Browse Lymphoma recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 6, 2026 Report an issue

ClinicalTrials.gov public records Last synced Nov 6, 2026, 3:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

5760

Shown on this page

Current sort

How Lymphoma studies are organized in the registry

Lymphoma records divide between Hodgkin and non-Hodgkin disease, and non-Hodgkin studies usually name the histology directly — diffuse large B-cell (DLBCL), follicular, mantle cell, and others. Subtype abbreviations are the most reliable narrowing terms because they appear in titles and condition fields verbatim.

Terms that often appear in related listings

DLBCL follicular lymphoma mantle cell Hodgkin

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 1213–1224 of 5,760 matching trials for Lymphoma.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome
Interventions: Pembrolizumab, Mogamulizumab; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Multiple Myeloma, Waldenstrom's Macroglobulinemia, Smoldering Multiple Myeloma, Lymphoblastic Lymphoma
Interventions: Not listed
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 656 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Mantle Cell Lymphoma, Non Hodgkin Lymphoma, Hematologic Malignancy
Interventions: Pirtobrutinib, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myeodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Neoplasm in Blast Phase
Interventions: LP-118; Drug
Lead sponsor: Newave Pharmaceutical Inc; Industry
Eligibility: 13 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: Chicago, Illinois • Boston, Massachusetts • Chapel Hill, North Carolina + 4 more

Conditions: Lymphoma
Interventions: carmustine, cyclophosphamide, etoposide, pharmacological study, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation; Drug · Other · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 10 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2026
U.S. locations: 1
States / cities: Duarte, California

Conditions: Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma
Interventions: Cryosurgery, Dendritic Cell Therapy, Laboratory Biomarker Analysis, Pembrolizumab, Pneumococcal 13-valent Conjugate Vaccine, Quality-of-Life Assessment; Procedure · Biological · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cannabis Use Disorder, Mild, Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe
Interventions: Peer Network Counseling-txt; Behavioral
Lead sponsor: The University of Tennessee, Knoxville; Other
Eligibility: 18 Years to 25 Years
Enrollment: 1,077 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: Fort Collins, Colorado • Knoxville, Tennessee

Conditions: Relapsed or Refractory Lymphomas, Advanced Solid Tumor
Interventions: LP-284; Drug
Lead sponsor: Lantern Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: West Valley City, Utah

Conditions: Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
Interventions: ABBV-525; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 13
States / cities: Los Angeles, California • New Haven, Connecticut • Miami Beach, Florida + 10 more

Conditions: Leukemia, Acute, AML, Adult, ALL, Adult, Myelodysplastic Syndromes
Interventions: Palliative Care Visits; Other
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Cutaneous T Cell Lymphoma
Interventions: APR-TD011 (RLF-TD011); Combination Product
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cutaneous T Cell Lymphoma
Interventions: CLn Body Wash; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

About this Lymphoma clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Lymphoma as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Lymphoma.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Lymphoma clinical trials

How Lymphoma studies are organized in the registry

Filter and sort this condition

Live official records

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma

Cannabis Use Disorder Treatment Study

Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS

Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution

Pilot Study to Characterize the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of CLn® Skin Care Body Wash

About this Lymphoma clinical trials directory page